Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension and Hyperlipidemia
Interventions: HTN and Medication Adherence; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005%, placebo; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 2
States / cities: Lakeland, Florida • Bourbonnais, Illinois

Conditions: Hypertension, Self-Management, Technology, Quality of Life
Interventions: OPTIMA-BP Intervention; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 50 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: Salt Pills, Placebo Pills; Dietary Supplement
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions: Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution; Drug · Other
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Roswell, Georgia

Conditions: Resistant Hypertension
Interventions: Splanchnic Nerve Denervation, Renal Denervation Only; Device
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Pulmonary Hypertension
Interventions: Hymecromone (H01), Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Arterial Hypertension
Interventions: AV-101, Placebo; Drug
Lead sponsor: Aerovate Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: Glaucoma, Open-Angle
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more

Conditions: Hypertension
Interventions: COREG CR, Lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Carotid Atherosclerosis, Cerebrovascular Accident, Diabetes Mellitus, Hypercholesterolemia, Hypertension
Interventions: cytokine and leukocyte activation profile; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Open-angle Glaucoma, Oular Hypertension
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Nutrition Disorders, Diabetes, Hypertension, Cancer, Depression, Obesity, Physical Activity
Interventions: Treatment; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 7 Years to 115 Years
Enrollment: 7,192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cardiovascular Diseases, Right Heart Failure, Cardiac Disease
Interventions: CorVista Capture; Device
Lead sponsor: Analytics For Life; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Marietta, Georgia • Maywood, Illinois + 13 more

Conditions: Glaucoma
Interventions: American Academy of Ophthalmology Glaucoma Educational Tape; Behavioral
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Fluoxetine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 16 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Hypertension
Interventions: nab-sirolimus; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more

Conditions: Hypertension, Pre-Hypertension
Interventions: DASH-4-Teens, Routine Care; Behavioral · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 11 Years to 18 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Intra-ocular pressure measurement (IOP); Other
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Disease
Interventions: Acthar; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pollution; Exposure, Hypertension, Pollution Related Respiratory Disorder
Interventions: Solar lighting system; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Gamification and Medication Adherence (GAME Adherence)

Cosopt Versus Xalatan

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

Vascular Responses to Sympathetic Activation and Altered Shear Rate: The Impact of Hypertension and Sodium Intake

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

The RESPLASH Study

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

Potential Risk Factors for Stroke

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Cooking for Health Optimization With Patients

Repository of Phase Signals for Pulmonary Hypertension Algorithm Development

The Effect of Education on Patient Compliance

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Water Drinking Test in Patients With Occludable Angle

ACTH Treatment of APOL1- Associated Nephropathy

Solar Lighting to Reduce Indoor Air Pollution in Rural Uganda